NNOX

Nanox and Vertec Scientific Enter Exclusive Sales Reseller Agreement for the Commercialization of Nanox.AI Bone Solution (HealthOST) in the United Kingdom

Nanox Secures UK Exclusive HealthOST License with Vertec to Expand AI Bone Health

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 &lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Nanox announced a three-year UK exclusive reseller deal with Vertec for HealthOST bone solution, an FDA-cleared AI tool. The agreement includes minimum annual commitments, expanding Nanox.AI’s footprint in the UK via Vertec’s DXA network. With NICE endorsing HealthOST and NHS uptake potential, the arrangement could create a near-term revenue path, though financial terms were not disclosed.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Nanox AI signs UK exclusive license with Vertec for HealthOST bone solution. Three-year term; minimum annual commitments apply.</li><li>HealthOST is FDA-cleared and UKCA/CE-marked AI software. Analyzes spine from CT scans for osteoporosis with vertebral metrics.</li><li>NICE recommended HealthOST for NHS opportunistic detection in Nov 2025.</li><li>Vertec will market HealthOST in the UK under exclusive license.</li><li>Announcement date Aug 18, 2026; term signals near-term rollout.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>Nanox Imaging Ltd. (NNOX): Announces UK exclusive HealthOST license via Vertec; expands AI bone health strategy and potential revenue stream.</li><li>Vertec Scientific Ltd. (NA): UK-based bone health solutions provider; exclusive marketing/resale rights secured; supports UK rollout.</li></ul>
 </section>

 <section data-block="category">
 <h3>Corporate Developments</h3>
 Category: Corporate Developments. The press release describes a strategic partnership expansion for Nanox.AI, signaling potential near-term revenue and geographic scaling of HealthOST; assessment of financial terms and rollout will determine magnitude of impact.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>UK exclusive license with minimum commitments could unlock near-term revenue.</li><li>Vertec&#039;s UK DXA footprint may accelerate HealthOST uptake in NHS settings.</li><li>No disclosed financial terms; execution risk if minimums underperform.</li><li>NICE endorsement in 2025 provides favorable uptake tailwinds.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>Three-year initial term for UK exclusive license.</li><li>Minimum annual license commitments.</li><li>HealthOST is FDA-cleared AI software for spine analysis.</li><li>UKCA/CE-marked HealthOST AI solution.</li><li>NICE recommended HealthOST for NHS use in November 2025.</li><li>Announcement date: August 18, 2026.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Bullish near-term on UK revenue potential; monitor rollout progress and disclosed terms.
 </section>
</section>


<article>
 <header>
 <h2>Nanox and Vertec Scientific Enter Exclusive Sales Reseller Agreement for Nanox.AI HealthOST in the United Kingdom</h2>
 </header>

 Initial three-year term includes minimum annual license commitments

 <section aria-label="Announcement overview">
 PETACH TIKVA, ISRAEL, August 18, 2026 — Nanox Imaging Ltd. (NASDAQ: NNOX) today announced its subsidiary Nanox AI Ltd. entered into a sales reseller agreement with Vertec Scientific Ltd. for the commercialization of Nanox.AI bone solution (HealthOST) in the United Kingdom. The agreement grants Vertec an exclusive license to market and resell HealthOST in the United Kingdom, subject to Vertec satisfying minimum annual license commitments, over an initial three-year term.
 </section>

 <section aria-label="Agreement terms">
 <h3>Key terms of the exclusive UK license</h3>
 <ul>
 <li>Exclusive license to market and resell HealthOST in the United Kingdom</li>
 <li>Subject to minimum annual license commitments by Vertec</li>
 <li>Over an initial three-year term</li>
 <li>HealthOST is FDA-cleared and UKCA/CE-marked AI software</li>
 </ul>
 </section>

 <section aria-label="HealthOST product description">
 <h3>HealthOST product overview and capabilities</h3>
 Nanox.AI bone solution (HealthOST) is an FDA-cleared and UKCA/CE-marked AI software solution that analyzes eligible routine CT scans. Nanox.AI bone solution (HealthOST) is an AI-enabled image processing software that provides qualitative and quantitative analysis of the spine from CT images to support clinicians in the evaluation and assessment of musculoskeletal disease of the spine, such as osteoporosis. The software provides vertebral labeling, vertebral height-loss measurements and vertebral bone-attenuation measurements.
 Since the CT scans analyzed by HealthOST were performed for other clinical indications, no additional imaging, radiation or patient time is required, enabling opportunistic assessment from routine CT scans. HealthOST is seamlessly integrated with existing picture archiving and communication systems (PACS) and can enable timely and appropriate preventive care.

 In November 2025, the National Institute for Health and Care Excellence (NICE) recommended HealthOST, as well as a previous version, HealthVCF, among five AI technologies for National Health Service (NHS) use "as options to aid the opportunistic detection of vertebral fragility fractures (VFFs)."
 </section>

 <section aria-label="Background on Vertec">
 <h3>Vertec Scientific: UK-based bone health solutions provider</h3>
 Vertec is a UK-based provider of DXA and bone health solutions, serving hospitals, clinics, and healthcare providers across the UK. First established in Berkshire in 1979, Vertec has built nearly five decades of experience as one of the UK's leading DXA suppliers, supported by nationwide, OEM-authorized engineering coverage and a team of clinically trained Applications and Product Specialists.
 </section>

 <section aria-label="Executive quotes">
 <h3>Executive remarks</h3>
 <blockquote>Erez Meltzer, Chief Executive Officer and Acting Chairman of Nanox, said: "This agreement expands the reach of our AI bone solution into the UK market and reflects our continued momentum in bringing AI-driven bone health assessment to healthcare providers. Vertec Scientific's established presence in DXA and bone health solutions makes them a strong partner to support this rollout across the UK."</blockquote>
 <blockquote>Kate O’Reilly, Managing Director of Vertec, added: "We are delighted to bring HealthOST to healthcare providers across the UK. Osteoporosis and vertebral fractures too often go undetected until it's too late, and this technology gives clinicians a straightforward way to identify at-risk patients from routine scans, enabling more timely and proactive interventions. We look forward to working with Nanox AI to expand access to this solution across the UK."</blockquote>
 </section>

 <section aria-label="About Nanox">
 <h3>About Nanox</h3>
 NANOX (NASDAQ:NNOX) is focused on driving the world's transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.
 Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.
 Nanox's vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.
 The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT capabilities.
 </section>
</article>

Nanox announced a three-year UK exclusive reseller deal with Vertec for HealthOST bone solution, an FDA-cleared AI tool. The agreement includes minimum annual commitments, expanding Nanox.AI’s footprint in the UK via Vertec’s DXA network. With NICE endorsing HealthOST and NHS uptake potential, the arrangement could create a near-term revenue path, though financial terms were not disclosed.

nanox-and-vertec-scientific-enter-exclusive-sales-reseller-agreement-for-the-commercialization-of-nanox-ai-bone-solution-healthost-in-the-united-kingdom

News insight

Nanox and Vertec Scientific Enter Exclusive Sales Reseller Agreement for the Commercialization of Nanox.AI Bone Solution (HealthOST) in the United Kingdom

AI summary

Sentiment rationale

Key facts

Corporate Developments